European regulators greenlit Fractyl Health’s clinical test of a GLP-1 gene therapy, as developers race to replace daily or weekly GLP-1 drug dosing with a potentially one-time treatment. The clearance positions the Boston-area company to proceed in Europe with a program targeting the same obesity-and-metabolism market expectations that drive intense competition among GLP-1-focused therapies. The decision also highlights regulators’ growing willingness to review gene therapy programs aimed at metabolic disease, not only rare genetic disorders. If the study expands the evidence base on safety and durability, it could sharpen the strategic roadmap for companies exploring “chronic control” through in vivo biology. For the category, the new trial adds to the momentum toward longer-interval interventions, even as existing GLP-1 drug uptake continues to be shaped by practical administration constraints.